c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential.
Previous studies have demonstrated that c-Src tyrosine kinase interacts specifically with ErbB2, but not with other members of the epidermal growth factor receptor (EGFR) family. To identify the site of interaction, we recently used a chimeric EGFR/ErbB2 receptor approach to show that c-Src requires the kinase region of ErbB2 for binding. Here, we demonstrate that retention of a conserved amino acid motif surrounding tyrosine 877 (referred to here as EGFR(YHAD)) is sufficient to confer binding to c-Src. Surprisingly the association of c-Src was not dependent on its SH2 or SH3 domain or on the phosphorylation or kinase activity of the receptor. We further show that the chimeric EGFRs that contain the Y877 motif are transforming in vitro and in vivo following ligand stimulation. Transformation was also partially dependent on sustained activation of Stat3. Finally, we demonstrate that EGFRs with mutations in the catalytic domain, originally identified in lung cancer and conferring increased sensitivity to gefitinib and erlotinib, two EGFR kinase inhibitors, gained the capacity to bind c-Src. Moreover, transformation by these EGFR mutants was inhibited by Src inhibitors regardless of their sensitivities to gefitinib and erlotinib. These observations have important implications for understanding the molecular basis for resistance to EGFR inhibitors and implicate c-Src as a critical signaling molecule in EGFR mutant-induced transformation.
Marcotte
Richard
R
Goodman Cancer Center, Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Zhou
Lixin
L
Kim
Harold
H
Roskelly
Calvin D
CD
Muller
William J
WJ
D000818:Animals; D001710:Biotin / Q000378:metabolism; D020134:Catalytic Domain; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D002478:Cells, Cultured; D004705:Endocytosis; D066246:ErbB Receptors / Q000378:metabolism; D005347:Fibroblasts / Q000201:enzymology; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology; D051379:Mice; D009154:Mutation / Q000235:genetics; D011485:Protein Binding; D011487:Protein Conformation; D016392:Proto-Oncogene Proteins pp60(c-src) / Q000737:chemistry* / Q000378:metabolism*; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D050796:STAT3 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction
D001710:Biotin; D066246:ErbB Receptors; D016392:Proto-Oncogene Proteins pp60(c-src); D018719:Erb-b2 Receptor Tyrosine Kinases; D050796:STAT3 Transcription Factor
Oncogene. 1995 Jul 20;11(2):271-9
7542762
Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):83-7
7506422
Mol Cell Biol. 2002 Apr;22(8):2427-40
11909938
J Pathol. 1996 Dec;180(4):383-8
9014858
Adv Cancer Res. 1994;64:111-23
7879656
J Cell Sci. 2004 Mar 1;117(Pt 7):989-98
14996930
Mol Cell Biol. 1994 Jan;14(1):735-43
7903421
Carcinogenesis. 2007 Jul;28(7):1408-17
17372273
Exp Cell Res. 2008 Oct 15;314(17):3093-106
18793634
Cancer Res. 2002 Aug 15;62(16):4781-90
12183438
Trends Biochem Sci. 2007 Aug;32(8):351-6
17627826
Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6981-5
7542783
Mol Cell Biol. 2007 Jan;27(1):220-8
17030621
Mol Cell Biol. 1996 Apr;16(4):1595-603
8657134
J Urol. 1990 Jul;144(1):47-52
2359180
Structure. 2005 Jun;13(6):861-71
15939018
Oncogene. 2005 Nov 17;24(51):7599-607
16170374
Oncogene. 1995 Nov 2;11(9):1801-10
7478608
Oncogene. 2004 Oct 18;23(48):7910-7
15489909
Science. 1987 Jul 10;237(4811):178-82
2885917
Cell. 1987 Dec 24;51(6):1063-70
3500791
Science. 1987 Jan 9;235(4785):177-82
3798106
Cancer Res. 2006 Apr 1;66(7):3764-72
16585203
J Biol Chem. 1999 Mar 19;274(12):8335-43
10075741
Oncogene. 2007 Oct 25;26(49):6968-78
17486068
Mol Cell Biol. 1998 May;18(5):2553-8
9566875
Proc Natl Acad Sci U S A. 1985 Oct;82(19):6497-501
2995967
J Virol. 1996 Mar;70(3):1323-30
8627648
Oncogene. 2004 Oct 18;23(48):7918-27
15489910
J Cell Biol. 1998 Oct 19;143(2):533-45
9786961
Int J Biochem Cell Biol. 2007;39(12):2173-82
17855153
Cancer Res. 1988 Sep 15;48(18):5119-23
3044581
Pathol Int. 2007 May;57(5):233-44
17493170
Mol Cell. 2003 Sep;12(3):541-52
14527402
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14707-12
14657361
Breast Cancer Res. 2002;4(5):176-8
12223119
J Cell Biol. 1989 Mar;108(3):1127-38
2466037
Mol Biol Cell. 2001 Jun;12(6):1897-910
11408594
Nat Rev Cancer. 2007 Mar;7(3):169-81
17318210
Exp Cell Res. 2008 Jan 15;314(2):413-9
17927978
Cell. 2006 Aug 11;126(3):489-502
16901783
Biochem Biophys Res Commun. 1995 May 25;210(3):844-51
7539262
Genes Dev. 1994 Jan;8(1):23-32
7507074
Curr Opin Struct Biol. 2006 Dec;16(6):676-85
17079133
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1415-20
9990038
Cancer Res. 1992 Sep 1;52(17):4773-8
1380891
J Cell Biol. 1992 Jul;118(2):321-33
1378446
Nat Cell Biol. 2001 Sep;3(9):785-92
11533657
J Cell Biol. 2000 Jan 24;148(2):385-97
10648571
Oncogene. 2009 Apr 23;28(16):1821-32
19305428
J Clin Invest. 1989 Jun;83(6):2025-33
2498394
Front Biosci. 1997 Oct 15;2:d501-18
9331427
Trends Cell Biol. 2006 Dec;16(12):649-56
17085050
J Biol Chem. 1997 Nov 28;272(48):30185-90
9374500
Biochem Biophys Res Commun. 1995 Oct 24;215(3):1078-87
7488034
Mol Cancer Res. 2003 Nov;1(13):931-9
14638865
Cancer Res. 2006 Mar 15;66(6):3162-8
16540667
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7849-53
7544006